Generic Drugs Market Size, Share, and Trends 2024 to 2033

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology (Premium Insights)

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Generic Drugs Market 

5.1. COVID-19 Landscape: Generic Drugs Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Generic Drugs Market, By Drug Type

8.1. Generic Drugs Market Revenue and Volume, by Drug Type, 2024-2033

8.1.1. Simple Generics

8.1.1.1. Market Revenue and Volume Forecast (2021-2033)

8.1.2. Super Generics

8.1.2.1. Market Revenue and Volume Forecast (2021-2033)

Chapter 9. Global Generic Drugs Market, By Brand

9.1. Generic Drugs Market Revenue and Volume, by Brand, 2024-2033

9.1.1. Pure generic drugs

9.1.1.1. Market Revenue and Volume Forecast (2021-2033)

9.1.2. Branded generic drugs

9.1.2.1. Market Revenue and Volume Forecast (2021-2033)

Chapter 10. Global Generic Drugs Market, By Route of Drug Administration 

10.1. Generic Drugs Market Revenue and Volume, by Route of Drug Administration, 2024-2033

10.1.1. Oral

10.1.1.1. Market Revenue and Volume Forecast (2021-2033)

10.1.2. Injection

10.1.2.1. Market Revenue and Volume Forecast (2021-2033)

10.1.3. Cutaneous

10.1.3.1. Market Revenue and Volume Forecast (2021-2033)

10.1.4. Others

10.1.4.1. Market Revenue and Volume Forecast (2021-2033)

Chapter 11. Global Generic Drugs Market, By Therapeutic Application

11.1. Generic Drugs Market Revenue and Volume, by Therapeutic Application, 2024-2033

11.1.1. Central Nervous System (CNS)

11.1.1.1. Market Revenue and Volume Forecast (2021-2033)

11.1.2. Cardiovascular

11.1.2.1. Market Revenue and Volume Forecast (2021-2033)

11.1.3. Infectious Diseases

11.1.3.1. Market Revenue and Volume Forecast (2021-2033)

11.1.4. Musculoskeletal Diseases

11.1.4.1. Market Revenue and Volume Forecast (2021-2033)

11.1.5. Respiratory

11.1.5.1. Market Revenue and Volume Forecast (2021-2033)

11.1.6. Oncology

11.1.6.1. Market Revenue and Volume Forecast (2021-2033)

11.1.7. Others

11.1.7.1. Market Revenue and Volume Forecast (2021-2033)

Chapter 12. Global Generic Drugs Market, By Distribution Channel

12.1. Generic Drugs Market Revenue and Volume, by Distribution Channel, 2024-2033

12.1.1. Retail Pharmacy

12.1.1.1. Market Revenue and Volume Forecast (2021-2033)

12.1.2. Hospital Pharmacy

12.1.2.1. Market Revenue and Volume Forecast (2021-2033)

12.1.3. Online and Others

12.1.3.1. Market Revenue and Volume Forecast (2021-2033)

Chapter 13. Global Generic Drugs Market, Regional Estimates and Trend Forecast

13.1. North America

13.1.1. Market Revenue and Volume Forecast, by Drug Type (2021-2033)

13.1.2. Market Revenue and Volume Forecast, by Brand (2021-2033)

13.1.3. Market Revenue and Volume Forecast, by Route of Drug Administration (2021-2033)

13.1.4. Market Revenue and Volume Forecast, by Therapeutic Application (2021-2033)

13.1.5. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)

13.1.6. U.S.

13.1.6.1. Market Revenue and Volume Forecast, by Drug Type (2021-2033)

13.1.6.2. Market Revenue and Volume Forecast, by Brand (2021-2033)

13.1.6.3. Market Revenue and Volume Forecast, by Route of Drug Administration (2021-2033)

13.1.6.4. Market Revenue and Volume Forecast, by Therapeutic Application (2021-2033)

13.1.6.5. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033) 

13.1.7. Rest of North America

13.1.7.1. Market Revenue and Volume Forecast, by Drug Type (2021-2033)

13.1.7.2. Market Revenue and Volume Forecast, by Brand (2021-2033)

13.1.7.3. Market Revenue and Volume Forecast, by Route of Drug Administration (2021-2033)

13.1.7.4. Market Revenue and Volume Forecast, by Therapeutic Application (2021-2033)

13.1.7.5. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)

13.2. Europe

13.2.1. Market Revenue and Volume Forecast, by Drug Type (2021-2033)

13.2.2. Market Revenue and Volume Forecast, by Brand (2021-2033)

13.2.3. Market Revenue and Volume Forecast, by Route of Drug Administration (2021-2033)

13.2.4. Market Revenue and Volume Forecast, by Therapeutic Application (2021-2033) 

13.2.5. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033) 

13.2.6. UK

13.2.6.1. Market Revenue and Volume Forecast, by Drug Type (2021-2033)

13.2.6.2. Market Revenue and Volume Forecast, by Brand (2021-2033)

13.2.6.3. Market Revenue and Volume Forecast, by Route of Drug Administration (2021-2033)

13.2.7. Market Revenue and Volume Forecast, by Therapeutic Application (2021-2033) 

13.2.8. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033) 

13.2.9. Germany

13.2.9.1. Market Revenue and Volume Forecast, by Drug Type (2021-2033)

13.2.9.2. Market Revenue and Volume Forecast, by Brand (2021-2033)

13.2.9.3. Market Revenue and Volume Forecast, by Route of Drug Administration (2021-2033)

13.2.10. Market Revenue and Volume Forecast, by Therapeutic Application (2021-2033)

13.2.11. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)

13.2.12. France

13.2.12.1. Market Revenue and Volume Forecast, by Drug Type (2021-2033)

13.2.12.2. Market Revenue and Volume Forecast, by Brand (2021-2033)

13.2.12.3. Market Revenue and Volume Forecast, by Route of Drug Administration (2021-2033)

13.2.12.4. Market Revenue and Volume Forecast, by Therapeutic Application (2021-2033)

13.2.13. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)

13.2.14. Rest of Europe

13.2.14.1. Market Revenue and Volume Forecast, by Drug Type (2021-2033)

13.2.14.2. Market Revenue and Volume Forecast, by Brand (2021-2033)

13.2.14.3. Market Revenue and Volume Forecast, by Route of Drug Administration (2021-2033)

13.2.14.4. Market Revenue and Volume Forecast, by Therapeutic Application (2021-2033)

13.2.15. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)

13.3. APAC

13.3.1. Market Revenue and Volume Forecast, by Drug Type (2021-2033)

13.3.2. Market Revenue and Volume Forecast, by Brand (2021-2033)

13.3.3. Market Revenue and Volume Forecast, by Route of Drug Administration (2021-2033)

13.3.4. Market Revenue and Volume Forecast, by Therapeutic Application (2021-2033)

13.3.5. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)

13.3.6. India

13.3.6.1. Market Revenue and Volume Forecast, by Drug Type (2021-2033)

13.3.6.2. Market Revenue and Volume Forecast, by Brand (2021-2033)

13.3.6.3. Market Revenue and Volume Forecast, by Route of Drug Administration (2021-2033)

13.3.6.4. Market Revenue and Volume Forecast, by Therapeutic Application (2021-2033)

13.3.7. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)

13.3.8. China

13.3.8.1. Market Revenue and Volume Forecast, by Drug Type (2021-2033)

13.3.8.2. Market Revenue and Volume Forecast, by Brand (2021-2033)

13.3.8.3. Market Revenue and Volume Forecast, by Route of Drug Administration (2021-2033)

13.3.8.4. Market Revenue and Volume Forecast, by Therapeutic Application (2021-2033)

13.3.9. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)

13.3.10. Japan

13.3.10.1. Market Revenue and Volume Forecast, by Drug Type (2021-2033)

13.3.10.2. Market Revenue and Volume Forecast, by Brand (2021-2033)

13.3.10.3. Market Revenue and Volume Forecast, by Route of Drug Administration (2021-2033)

13.3.10.4. Market Revenue and Volume Forecast, by Therapeutic Application (2021-2033)

13.3.10.5. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)

13.3.11. Rest of APAC

13.3.11.1. Market Revenue and Volume Forecast, by Drug Type (2021-2033)

13.3.11.2. Market Revenue and Volume Forecast, by Brand (2021-2033)

13.3.11.3. Market Revenue and Volume Forecast, by Route of Drug Administration (2021-2033)

13.3.11.4. Market Revenue and Volume Forecast, by Therapeutic Application (2021-2033)

13.3.11.5. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)

13.4. MEA

13.4.1. Market Revenue and Volume Forecast, by Drug Type (2021-2033)

13.4.2. Market Revenue and Volume Forecast, by Brand (2021-2033)

13.4.3. Market Revenue and Volume Forecast, by Route of Drug Administration (2021-2033)

13.4.4. Market Revenue and Volume Forecast, by Therapeutic Application (2021-2033)

13.4.5. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)

13.4.6. GCC

13.4.6.1. Market Revenue and Volume Forecast, by Drug Type (2021-2033)

13.4.6.2. Market Revenue and Volume Forecast, by Brand (2021-2033)

13.4.6.3. Market Revenue and Volume Forecast, by Route of Drug Administration (2021-2033)

13.4.6.4. Market Revenue and Volume Forecast, by Therapeutic Application (2021-2033)

13.4.7. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)

13.4.8. North Africa

13.4.8.1. Market Revenue and Volume Forecast, by Drug Type (2021-2033)

13.4.8.2. Market Revenue and Volume Forecast, by Brand (2021-2033)

13.4.8.3. Market Revenue and Volume Forecast, by Route of Drug Administration (2021-2033)

13.4.8.4. Market Revenue and Volume Forecast, by Therapeutic Application (2021-2033)

13.4.9. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)

13.4.10. South Africa

13.4.10.1. Market Revenue and Volume Forecast, by Drug Type (2021-2033)

13.4.10.2. Market Revenue and Volume Forecast, by Brand (2021-2033)

13.4.10.3. Market Revenue and Volume Forecast, by Route of Drug Administration (2021-2033)

13.4.10.4. Market Revenue and Volume Forecast, by Therapeutic Application (2021-2033)

13.4.10.5. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)

13.4.11. Rest of MEA

13.4.11.1. Market Revenue and Volume Forecast, by Drug Type (2021-2033)

13.4.11.2. Market Revenue and Volume Forecast, by Brand (2021-2033)

13.4.11.3. Market Revenue and Volume Forecast, by Route of Drug Administration (2021-2033)

13.4.11.4. Market Revenue and Volume Forecast, by Therapeutic Application (2021-2033)

13.4.11.5. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)

13.5. Latin America

13.5.1. Market Revenue and Volume Forecast, by Drug Type (2021-2033)

13.5.2. Market Revenue and Volume Forecast, by Brand (2021-2033)

13.5.3. Market Revenue and Volume Forecast, by Route of Drug Administration (2021-2033)

13.5.4. Market Revenue and Volume Forecast, by Therapeutic Application (2021-2033)

13.5.5. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)

13.5.6. Brazil

13.5.6.1. Market Revenue and Volume Forecast, by Drug Type (2021-2033)

13.5.6.2. Market Revenue and Volume Forecast, by Brand (2021-2033)

13.5.6.3. Market Revenue and Volume Forecast, by Route of Drug Administration (2021-2033)

13.5.6.4. Market Revenue and Volume Forecast, by Therapeutic Application (2021-2033)

13.5.7. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)

13.5.8. Rest of LATAM

13.5.8.1. Market Revenue and Volume Forecast, by Drug Type (2021-2033)

13.5.8.2. Market Revenue and Volume Forecast, by Brand (2021-2033)

13.5.8.3. Market Revenue and Volume Forecast, by Route of Drug Administration (2021-2033)

13.5.8.4. Market Revenue and Volume Forecast, by Therapeutic Application (2021-2033)

13.5.8.5. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)

Chapter 14. Company Profiles

14.1. Mylan N.V.

14.1.1. Company Overview

14.1.2. Product Offerings

14.1.3. Financial Performance

14.1.4. Recent Initiatives

14.2. Abbott Laboratories

14.2.1. Company Overview

14.2.2. Product Offerings

14.2.3. Financial Performance

14.2.4. Recent Initiatives

14.3. ALLERGAN

14.3.1. Company Overview

14.3.2. Product Offerings

14.3.3. Financial Performance

14.3.4. Recent Initiatives

14.4. Teva Pharmaceutical Industries Ltd.

14.4.1. Company Overview

14.4.2. Product Offerings

14.4.3. Financial Performance

14.4.4. Recent Initiatives

14.5. Eli Lilly and Company

14.5.1. Company Overview

14.5.2. Product Offerings

14.5.3. Financial Performance

14.5.4. Recent Initiatives

14.6. STADA Arzneimittel AG

14.6.1. Company Overview

14.6.2. Product Offerings

14.6.3. Financial Performance

14.6.4. Recent Initiatives

14.7. GlaxoSmithKline Plc.

14.7.1. Company Overview

14.7.2. Product Offerings

14.7.3. Financial Performance

14.7.4. Recent Initiatives

14.8. Baxter International Inc.

14.8.1. Company Overview

14.8.2. Product Offerings

14.8.3. Financial Performance

14.8.4. Recent Initiatives

14.9. Pfizer Inc.

14.9.1. Company Overview

14.9.2. Product Offerings

14.9.3. Financial Performance

14.9.4. Recent Initiatives

14.10. Sandoz International GmbH

14.10.1. Company Overview

14.10.2. Product Offerings

14.10.3. Financial Performance

14.10.4. Recent Initiatives

Chapter 15. Research Methodology

15.1. Primary Research

15.2. Secondary Research

15.3. Assumptions

Chapter 16. Appendix

16.1. About Us

16.2. Glossary of Terms